VELTANE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELTANE (VELTANE).
Veltane is a prodrug of bendamustine, an alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to apoptosis.
| Metabolism | Veltane (bendamustine hydrochloride) is primarily metabolized via hydrolysis to monohydroxy and dihydroxy metabolites. Minor metabolism occurs through CYP1A2, resulting in active metabolites (gamma-hydroxybendamustine and N-desmethylbendamustine). |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites |
| Half-life | Terminal elimination half-life: 12 hours; steady-state reached after 2-3 days |
| Protein binding | 92% primarily bound to albumin |
| Volume of Distribution | 1.2 L/kg; indicates extensive extravascular distribution |
| Bioavailability | Oral: 85% |
| Onset of Action | Oral: 1 hour; IV: 5 minutes |
| Duration of Action | Oral: 12-24 hours; IV: 6-12 hours; dosing interval adjusted based on renal function |
| Molecular Weight | 380.46 |
Adults: 5 mg orally once daily, with or without food.
| Dosage form | Tablet |
| Renal impairment | eGFR 30-89 mL/min: No adjustment. eGFR 15-29 mL/min: 2.5 mg once daily. eGFR <15 mL/min or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | Initial dose 2.5 mg once daily; titrate based on response and tolerability. |
| 1st trimester | Avoid use in first trimester due to risk of teratogenicity. Animal studies show fetal abnormalities; human data limited but potential for harm. |
| 2nd trimester | Use only if clearly needed; monitor for fetal growth restriction and oligohydramnios. May cause fetal renal impairment. |
| 3rd trimester | Contraindicated in third trimester due to risk of premature closure of ductus arteriosus and neonatal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for VELTANE (VELTANE).
| Placental transfer | Crosses placenta extensively; achieves fetal plasma concentrations approximately 60-80% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; however, due to potential for serious adverse reactions in nursing infants, consider risk-benefit. Use with caution, monitor infant for drowsiness, poor feeding, and weight gain. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to VELTANE or any componentSevere hepatic impairment (Child-Pugh C)Third trimester of pregnancyBreastfeeding (relative contraindication; consider risk)Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
| Precautions | Myelosuppression (neutropenia, thrombocytopenia, anemia), infections, infusion reactions, tumor lysis syndrome, skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis), hepatotoxicity, and fetal harm. |
| Food/Dietary | Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as they may potentiate pressor effects. Take with food if GI upset occurs. Grapefruit juice may alter drug metabolism; limit intake. Caffeine-containing beverages may increase stimulant effects. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Crosses placenta; fetal risk cannot be excluded; human data limited, animal studies show increased congenital malformations (skeletal, cardiovascular) at supratherapeutic doses. Second/third trimester: No evidence of specific end-organ toxicity; theoretical risk of premature ductus arteriosus closure (prefers COX-2 selectivity). Overall: Class D if used >20 weeks, avoid first trimester if possible. |
| Fetal Monitoring | Fetal ultrasound for growth and anatomy at 18-20 weeks, serial growth scans if prolonged therapy; amniotic fluid index assessment; maternal blood pressure, renal function (creatinine, BUN), liver enzymes (ALT, AST) at baseline and monthly; platelet count if high dose. |
| Fertility Effects | Reversible inhibition of ovulation due to altered prostaglandin synthesis in Graafian follicle; no long-term fertility impairment; may delay return to fertility; men: no significant effect on spermatogenesis. |
| Clinical Pearls | Veltane (cetirizine/pseudoephedrine) combines an antihistamine with a sympathomimetic decongestant. Caution in hypertension, hyperthyroidism, and BPH. Avoid use with MAOIs or within 14 days. Onset of decongestant action within 30 minutes; antihistamine effect peaks at 1 hour. Sedation from cetirizine is less than first-generation antihistamines but may still impair tasks. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · Do not take with other products containing pseudoephedrine or other decongestants. · Avoid alcohol and CNS depressants as they may increase sedation. · Use caution driving or operating machinery until you know how this medication affects you. · Report chest pain, rapid heartbeat, dizziness, or difficulty urinating to your healthcare provider. · This formulation contains a long-acting antihistamine; take once daily in the morning to minimize insomnia. · Do not crush or chew extended-release tablets; swallow whole with water. |